The Peter Attia Drive

The Peter Attia Drive will feature guests and experts that will offer advice and insight to help you optimize performance, health, longevity, critical thinking, and life. It’s hosted by Stanford M.D., TED speaker, and longevity expert Dr. Peter Attia, founder of Attia Medical, PC, a medical practice with offices in San Diego and New York City.

#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D. Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer’s disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer’s disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care. We discuss: Gayatri’s training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45]; How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15]; The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30]; Gayatri’s comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45]; Why forgetting names is usually normal and when word-finding problems become concerning [29:00]; Why women are at higher risk for Alzheimer's disease and how menopause influences cognition [33:45]; The promise and limitations of blood-based biomarkers for diagnosing Alzheimer's disease [40:15]; When preclinical Alzheimer's screening is appropriate and how to interpret positive biomarker results [45:00]; Case study: early Alzheimer's prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15]; Anti-amyloid therapies: balancing clinical benefit with ARIA risk using slow titration [51:45]; The aducanumab controversy, why it was discontinued, and why Gayatri would still choose it [1:00:00]; How anti-amyloid therapies cause ARIA, strategies for detecting and managing these complications, and how future therapies may improve safety and accessibility [1:03:30]; Two patient examples of exceptional responses to anti-amyloid therapy [1:12:30]; A multimodal approach to Alzheimer's treatment: combination therapy, MRI-guided TMS, GLP-1 receptor agonists, and more [1:15:00]; Vascular dementia, Lewy body dementia, and the overlap with Alzheimer's disease [1:21:00]; Lewy body dementia and Parkinson's disease: distinguishing two alpha-synuclein disorders [1:26:45]; Risk factors for Lewy body dementia and what remains unknown [1:36:15]; Treating menopause-related cognitive impairment: hormone therapy, brain rehabilitation, and balancing breast cancer risk [1:38:45]; How biomarkers changed Gayatri's perspective on the potential for Alzheimer's patients to improve [1:47:15]; The future of Alzheimer's care: AI, precision medicine, and personalized treatment [1:49:30]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41935320

Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast) 07/06/2026

Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast) In this “Ask Me Anything” (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably. We discuss: Peter’s humorous experience talking nutrition with a second grader [3:00]; Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:30]; Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:45]; The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [11:00]; Grip strength as a simple yet powerful predictor of all-cause mortality [17:15]; Is muscle strength causal or just a marker of health? [20:30]; Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [23:00]; How muscle mass and strength enhance healthspan by supporting metabolic health, inflammation control, recovery from illness, mobility, and fall prevention [24:15]; How muscle mass and strength decline with age, and why it’s essential to act early to slow decline and preserve function later in life [31:00]; The foundational principles of building muscle strength and size through resistance training [36:00]; How to apply “progressive overload” for long-term strength and muscle gains [40:00]; The difference between concentric and eccentric muscle contractions and how each impacts strength, hypertrophy, and injury prevention [45:15]; The differences between muscle fiber types, and how aging disproportionately affects fast-twitch fibers responsible for power [50:45]; How to effectively train for power [52:30]; Training intensity: the benefits and safety of using the “reps in reserve” method [53:30]; How to balance compound and isolation exercises in a workout routine, and why compound lifts are foundational [56:15]; Can bodyweight exercises build muscle as effectively as weight training? [58:15]; How women can effectively build strength and muscle: key considerations [59:45]; Effective methods for tracking progress in strength [1:01:45]; Effective methods for tracking progress in muscle mass, and how to interpret results from a DEXA scan [1:05:00]; How to balance workout frequency with recovery for optimal results [1:07:15]; How to recognize signs of overtraining and when to consider taking rest days [1:10:45]; Avoiding injury: how beginners or returning lifters can start resistance training safely [1:15:45]; Protein: recommended intake, quality sources, timing of consumption, and more [1:18:00]; How fasting and calorie restriction affect muscle mass and what can be done to minimize muscle loss [1:24:45]; Key nutritional factors beyond protein that support muscle growth: hydration, creatine, and recovery [1:28:15]; The impact of hormones, sleep, stress, and consistency on muscle building and recovery [1:29:15]; How to structure an effective workout routine for a younger person who is new to resistance training [1:32:00]; How to modify beginner resistance training programs for older individuals to prioritize safety and gradual progress [1:36:00]; Should beginners start with machines or free weights when resistance training? [1:37:00]; How experienced lifters should modify their training to support healthspan and performance in later life [1:38:30]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41901475

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss 06/29/2026

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss In this “Ask Me Anything” (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your or our website at the . If you are not a subscriber, you can learn more about the subscriber benefits . We discuss: The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45]; Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]; How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15]; Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30]; Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15]; The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00]; Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45]; Why lean mass measurements are an imperfect proxy for muscle health and function [21:45]; The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00]; Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00]; Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00]; Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45]; Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00]; Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00]; Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45]; Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15]; Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00]; The risks of using gray-market retatrutide before FDA approval [52:15]; Key takeaways [54:30]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41698420

#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D. 06/22/2026

#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D. Renato Tomioka is a leading expert in reproductive medicine and gynecologic surgery whose unique skills allow him to diagnose and treat some of the most impactful yet frequently overlooked conditions affecting women’s health. In this episode, Renato explores endometriosis and adenomyosis, explaining what these conditions are, why they often go undiagnosed for years despite affecting millions of women worldwide, and how advances in MRI and specialized ultrasound are transforming diagnosis beyond traditional surgical laparoscopy. He discusses the decision-making process behind hormonal therapy versus surgery, how treatment strategies change when fertility preservation is a priority, and where IVF fits into the care pathway for women with endometriosis, adenomyosis, or age-related fertility decline. Renato also examines the profound effects of female age on egg quality and quantity, including the accelerating rise in chromosomal abnormalities after age 35, highlights common mistakes in both surgical and fertility management, and shares promising developments on the horizon for treating these conditions and preserving fertility. Follow Dr. Tomioka's work: Instagram: ; Website: We discuss: 0:00:00 - Intro 0:00:11 - Endometriosis: definition, prevalence, infertility risk, and theories of disease development 0:09:03 - The biology of endometriosis: estrogen dependence, progesterone resistance, and tumor-like growth mechanisms 0:13:25 - Adenomyosis explained: how it differs from endometriosis, why it develops, and its impact on reproductive health 0:18:52 - Recognizing endometriosis and adenomyosis: the “6 Ds” of endometriosis and key differences in clinical presentation 0:22:09 - Uterine fibroids: classification, symptoms, and the importance of fibroid location for bleeding and fertility 0:24:09 - Understanding endometriosis pain: lesion-driven pain, nerve involvement, central sensitization, and the importance of early treatment 0:28:26 - Endometriosis in young women: rising prevalence, delayed diagnosis, and barriers to care 0:33:11 - Modern diagnosis of endometriosis: specialized ultrasound, MRI, and the decline of diagnostic laparoscopy 0:45:52 - Clinical case example #1: Managing endometriosis in a young woman seeking pain relief while preserving future fertility 0:54:10 - Clinical case example #2: Comparing treatment strategies for symptom control versus fertility 1:01:24 - Endometriosis and fertility: the roles of age, embryo quality, IVF, and surgery 1:11:50 - Clinical case example #3: Managing adenomyosis after failed IVF transfers to improve implantation and pregnancy outcomes 1:20:51 - The funding gap in endometriosis research: disease burden, economic impact, and growing awareness 1:22:01 - Clinical case example #4: Surgical decision-making in endometriosis—balancing pain relief, fertility preservation, and common treatment pitfalls 1:27:43 - Common misconceptions about fertility: maternal age, embryo aneuploidy, the inefficiency of human reproduction, and the limits of IVF 1:34:23 - Elective egg freezing: timing, success rates, the fertility funnel, and the tradeoffs of fertility preservation 1:45:49 - Emerging fertility technologies: mitochondrial replacement, ovarian tissue preservation, stem-cell-derived eggs, and current limitations 1:55:10 - The future of endometriosis treatment: new guidelines, biologic therapies, and unanswered questions about IVF 1:58:30 - Why earlier diagnosis matters: reducing years of suffering from endometriosis and adenomyosis Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41659140

#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy 06/15/2026

#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy In this episode, Peter explores the critical topic of breast cancer screening, examining why thousands of women continue to die from breast cancer each year despite the availability of effective screening tools. He explains the strengths and limitations of current screening strategies, reviews the recommendations from major medical organizations, and discusses why screening guidance can often seem confusing or contradictory. Peter outlines a practical framework for understanding breast cancer risk and personalizing screening decisions, including when to begin screening, how frequently to screen, and which imaging modalities may be most appropriate based on an individual’s risk profile. Throughout the episode, he emphasizes that while population-based guidelines provide an important foundation, optimizing outcomes requires a more personalized approach aimed at helping women make informed screening decisions that can improve the chances of early detection and successful treatment. We discuss: Why women still die from breast cancer: the benefits of screening, the problem of under-screening, and the need for risk-based screening strategies [1:45]; Current screening recommendations, why they differ between organizations, and the importance of personalized screening decisions [6:30]; A framework for personalizing screening [8:45]; Assessing baseline breast cancer risk: genetics, family history, breast density, lifestyle factors, and the role of risk calculators in personalized screening [9:30]; Balancing cancer detection and false positives: how breast cancer risk influences screening intensity and imaging choices [17:45]; Mammography as the foundation of breast cancer screening: detecting ductal carcinoma in situ (DCIS) and the advantages of 3D versus 2D mammography [21:00]; MRI for high-risk women: the benefits of supplemental screening, abbreviated MRI, and the emerging role of contrast-enhanced mammography [23:00]; The role of ultrasound: supplemental cancer detection, diagnostic evaluation, and limitations compared with mammography and MRI [26:00]; Choosing the right breast cancer screening strategy: imaging modality selection, screening hierarchies, and the importance of imaging center quality [28:00]; How often should you screen for breast cancer? [30:15]; At what age should you start screening? [37:30]; Breast cancer in younger women: aggressive tumor biology, BRCA-related risk, breast density, and individualized decisions about when to begin screening [41:45]; Inflammatory breast cancer, the limitations of screening mammography for symptomatic disease, and the importance of promptly evaluating new breast symptoms in both women and men [44:45]; From risk assessment to personalized screening: a practical framework for reducing breast cancer mortality through earlier and more effective detection [46:30]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41542070

#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D. 06/08/2026

#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D. Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain’s cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer’s disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation. We discuss: The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45]; How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45]; How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00]; How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-containing lipoproteins [29:00]; How apoB structure influences LDL receptor binding and LDL clearance [39:00]; How neurons acquire cholesterol from apoE-containing lipoproteins and why desmosterol serves as a unique marker of cholesterol synthesis in the brain [41:45]; The difference between the APOE gene and the apoE protein, the major APOE genotypes found in humans, and how APOE4 influences Alzheimer's disease risk [48:45]; HDL function beyond cholesterol: immune function, protein cargo, and communication with the brain [53:30]; How APOE4-associated defects in brain cholesterol transport may promote Alzheimer's disease: amyloid production, neuronal cholesterol homeostasis, and cholesterol clearance [58:00]; Statins and brain health: reviewing the evidence of the potential impact of statins on cognition and Alzheimer's disease risk [1:09:00]; Desmosterol and 24S-hydroxycholesterol as biomarkers of brain cholesterol metabolism and statin effects [1:17:15]; Possible cognitive benefits of ezetimibe beyond lowering apoB [1:19:30]; EPA, DHA, and the evidence for omega-3 fatty acids in brain health [1:23:15]; Obicetrapib: an emerging CETP inhibitor with potential implications for both cardiovascular and brain health [1:31:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41503050

#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements 06/01/2026

#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements In this episode, Peter dives into the pharmacology of sleep, exploring where sleep medications fit within the broader framework of achieving healthy, restorative sleep. He explains why sleep is a biological imperative, why behavioral and environmental interventions must remain the foundation of good sleep, and how medications can serve as useful tools when carefully matched to a person’s specific sleep problem. Peter examines the major classes of prescription sleep medications, including how they work, their effects on sleep architecture, their duration of action, side effects, and risks of tolerance and dependence. He also discusses the dangers of using sleep drugs without a clear understanding of the underlying problem being treated, the role of medications as short-term bridges during periods of acute stress, pain, or anxiety, and the promise that newer drugs like DORAs may hold for Alzheimer’s prevention in high-risk individuals. Finally, Peter reviews the evidence for select off-label medications and supplements commonly used for sleep. We discuss: The biological foundations of sleep, the major drivers of sleep dysfunction, and the role sleep medications can play when appropriately matched to specific sleep problems [1:00]; Sleep hygiene, circadian alignment, and the medical causes of insomnia: building the foundation for effective sleep treatment [7:15]; Understanding insomnia: hyperarousal, CBT-I, paradoxical insomnia, and why different sleep problems require different treatments [12:45]; The difference between sedation and physiologic sleep: sleep architecture, restorative sleep stages, and matching medications to specific sleep problems [17:00]; Benzodiazepines for insomnia: mechanisms, effects on sleep architecture, and the risks of long-term use [18:45]; Z-drugs for insomnia: how Ambien, Sonata, and Lunesta work, and the ongoing risks of sleep medications targeting GABA systems [23:00]; Dual orexin receptor antagonists (DORAs) and the future of sleep medicine: orexin signaling, sleep architecture, and the emerging connection between sleep and Alzheimer’s disease [27:15]; Melatonin for circadian timing: how timing signals differ from sedatives in the treatment of sleep disorders [36:30]; Trazodone for insomnia: preserving deep sleep while minimizing the risks of traditional sedative-hypnotics [42:00]; First-generation antihistamines for sleep: short-term sedation, anticholinergic risks, and concerns about long-term cognitive health [44:00]; Sleep supplements and the evidence behind them: glycine, magnesium, ashwagandha, phosphatidylserine, and more [45:45]; Takeaways: supplement quality, individualized sleep treatment, and the importance of matching interventions to the biology of insomnia [52:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41386410

#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they’re working for you 05/25/2026

#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they’re working for you In this “Ask Me Anything” (AMA) episode, Peter explores how to think critically about medications and supplements by focusing not on whether an intervention is inherently “good” or “bad,” but on whether it makes sense for a specific person with a specific problem. He explains why clearly defining the problem matters more than choosing the intervention itself, how the intended purpose of a medication or supplement should influence the standard of evidence required, and why mechanistic reasoning alone is rarely enough to justify taking something. Peter also examines how baseline risk shapes the true benefit of an intervention, why relative risk statistics can be misleading without proper context, and how to weigh not only side effects, but also cost, inconvenience, and opportunity cost when deciding whether something is worth taking. Additionally, he discusses practical ways to evaluate whether a supplement is actually having a meaningful effect, how to think about discontinuing therapies, why supplements deserve far more skepticism than they often receive, and the small group of over-the-counter supplements he believes may offer a reasonable risk-reward trade-off. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your or our website at the . If you are not a subscriber, you can learn more about the subscriber benefits . We discuss: How to properly define health problems before considering medications or supplements [1:45]; How the intended purpose of an intervention should determine evidence standards and risk tolerance [5:00]; Understanding the hierarchy of evidence for medications and supplements and avoiding the mistake of treating weak evidence as clinical proof [9:00]; Why mechanistic explanations can be misleading when evaluating longevity interventions [13:15]; How baseline risk—and the distinction between relative and absolute risk reduction—changes the real-world benefit of medications and supplements [18:15]; Thinking beyond side effects: the many forms of downside associated with medications and supplements [22:45]; Why medications and supplements require different standards of trust and evidence [26:00]; How to structure meaningful self-experiments with medications and supplements to determine if it’s they’re working [30:30]; How to monitor the effects of medications and supplements without fooling yourself [32:30]; How to periodically reevaluate and potentially discontinue medications and supplements [35:15]; The biggest risks and failure modes of over-the-counter supplements: efficacy, poor quality control, contamination, interactions, toxicity, and marketing-driven overuse [38:30]; Why the US supplement regulatory system creates unreliable products [41:45]; A practical framework for evaluating medications and supplements [46:30]; Over-the-counter supplements with the best balance of evidence and low downside risk [48:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41335030

#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results 05/18/2026

#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results In this episode, Peter explores the complex and often misunderstood world of genetic testing, building a practical framework for understanding what these tests can and cannot actually tell us about health and disease. He explains why some genetic findings can be genuinely life-changing while many others offer information that is far more probabilistic than deterministic, and why directly measuring the phenotype is often more valuable than inferring risk from DNA alone. Peter examines where genetics can provide meaningful insight across the major disease categories and where its predictive power is far more limited than many people assume. He also discusses how to think critically about different types of genetic tests, how to interpret results in the proper context, and how to avoid the common trap of accumulating more genetic information without gaining greater clarity or actionable insight. We discuss: Genetic testing: understanding what it can reveal, where it falls short, and how to think about its clinical value [1:45]; The Human Genome Project: why decoding DNA did not immediately unlock the mysteries of disease [4:15]; The limitations of genetic testing: probabilistic risk, interpretive uncertainty, and the importance of phenotype [9:30]; Questions to ask when considering genetic testing [15:45]; Genetic testing in cardiovascular and metabolic disease: when genotype adds value beyond phenotype [17:00]; Genetic testing for inherited cardiac conditions: identifying hidden risk beyond routine screening [21:45]; Genetic testing for cancer risk: inherited syndromes, clinical utility, and the limits of consumer testing [24:00]; Genetic testing for neurodegenerative disease: risk prediction, planning, and the challenge of limited actionability [28:45]; Functional medicine genetic testing: the gap between biological plausibility and clinical evidence, and the supplement protocols that aren’t supported by evidence [32:45]; Pharmacogenetics: using genetic testing to guide medication selection and safety [38:45]; A framework for evaluating genetic tests according to effect size and clinical actionability [41:45]; The major types of genetic tests, and how each should be matched to the clinical question being asked [43:30]; Interpreting genetic test results: choosing the right testing laboratory and understanding what the findings actually mean [49:45]; Framework summary: why genetic testing is most valuable when it is guided by a clear question, matched with the appropriate test, and capable of meaningfully influencing decisions [56:45]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41287970

#391 ‒ Colorectal cancer screening: importance of early screening, colonoscopy as a screening and preventive tool, and how to build a personalized strategy 05/11/2026

#391 ‒ Colorectal cancer screening: importance of early screening, colonoscopy as a screening and preventive tool, and how to build a personalized strategy In this episode, Peter takes a deep dive into colorectal cancer (CRC) screening, explaining why it is one of the most preventable cancers and why getting screening right can have life-saving implications. He walks through how colorectal cancer develops and why it is uniquely well-suited to early detection and prevention, with a particular emphasis on the dual role of colonoscopy as both a diagnostic and therapeutic tool. Peter also examines the concerning rise in early-onset CRC among younger adults, highlighting why awareness and timely screening matter more than ever. The episode provides a practical guide to preparing for and evaluating the quality of a colonoscopy, including how to think about appropriate screening intervals and the real risks and tradeoffs involved. Finally, Peter explores the expanding landscape of non-invasive screening options, offering clear insight into what these alternatives can and cannot do so listeners can make informed decisions about their care at any age. We discuss: CRC statistics and goals for this episode [1:00]; Colorectal cancer development: polyp progression, risk types, and the window for prevention [4:00]; Why colorectal cancer is uniquely screenable: direct visualization and the dual role of colonoscopy [6:30]; Colonoscopy effectiveness: prevention through polyp removal and interpreting the NordICC trial data [8:15]; Rising colorectal cancer in younger adults: trends, possible causes, and the case for earlier screening [12:15]; Colonoscopy preparation: why bowel prep matters and how newer options improve the experience [16:45]; Colonoscopy quality, polyp miss rates, and personalized screening intervals [20:00]; Colonoscopy risks versus colorectal cancer risk: understanding the true risk-benefit tradeoff [29:30]; Non-invasive screening options for CRC: benefits, limitations, and their role alongside colonoscopy [37:00]; Colorectal cancer prevention principles: why screening matters and the role of colonoscopy [39:30]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41152035

#390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydration 05/04/2026

#390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydration In this “Ask Me Anything” (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it’s possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your or our website at the . If you are not a subscriber, you can learn more about the subscriber benefits . We discuss: Topics overview [1:15]; Using family history to assess disease risk: why it matters more than genetic testing and how to analyze it effectively [2:30]; Peter’s views that differ from conventional medicine: approaches to cardiovascular risk, cancer screening, nutrition, and more [10:30]; Risk tolerance in health decisions: weighing action versus inaction and avoiding low-benefit, high-risk interventions [16:00]; Why cardiovascular disease persists: delayed treatment, insufficient thresholds, and missed opportunities for early intervention [22:00]; Whether someone can be overweight yet metabolically healthy, and how fat distribution influences metabolic risk [26:45]; Strength training with limited time: how to maximize results with intensity and efficiency [30:00]; Designing a sustainable exercise routine: balancing volume, recovery, and enjoyment over time [34:45]; Reducing dementia risk: prioritizing exercise, sleep, and cardiometabolic health based on individual gaps [38:00]; Peter’s current skepticism toward NAD-related supplements and what evidence would be needed to change his view [40:45]; Hydration and electrolytes: factors that impact needs and when supplementation might be necessary [43:30]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/41033655

#389 - Thinking scientifically: why it's hard, why it matters, and a practical toolkit 04/27/2026

#389 - Thinking scientifically: why it's hard, why it matters, and a practical toolkit In this episode, Peter explores one of the most foundational topics underlying nearly everything discussed on the podcast: how to think scientifically. Framed as an introspective deep dive, he examines why scientific thinking is inherently difficult for humans, the cognitive biases and tendencies that make it challenging to separate belief from evidence, and why these challenges are even more consequential in today’s environment saturated with misinformation. He also offers a framework for improving our ability to evaluate claims, question assumptions, and identify a personal panel of experts, providing listeners with practical tools to become more disciplined and effective thinkers. We discuss: Topics to be covered and goals for this episode [2:00]; Scientific thinking: hypotheses, uncertainty, and the process of ruling out explanations [3:45]; How scientific knowledge differs from mathematical proof: useful approximations, evolving evidence, and acting under uncertainty [8:00]; Why scientific thinking is difficult: evolution, social instincts, and the need for deliberate practice [13:30]; Systems and tools designed to correct human bias [18:15]; How to think scientifically pt. 1: Notice when you're feeling certain [20:30]; How to think scientifically pt. 2: Judge the process, not just the conclusion [23:00]; How to think scientifically pt. 3: Notice when identity is shaping your beliefs [28:15]; How to think scientifically pt. 4: Don’t confuse criticism with understanding [33:45]; How to think scientifically pt. 5: Outsource your thinking carefully [36:15]; Evaluating who to trust: incentives, consensus, and red flags in scientific credibility [45:15]; Science as a self-correcting system: why updating with evidence is a strength, not a weakness [49:00]; The key principles of scientific thinking, and a practical framework for evaluating claims and improving judgment [50:45]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/40989140

#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives 04/20/2026

#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality. We discuss: The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30]; PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30]; The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00]; How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00]; Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00]; Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30]; Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to argue against PSA screening [29:45]; Prostate cancer screening today: improved tools, flawed guidelines, and preventable mortality [33:45]; How finasteride and similar drugs suppress PSA levels and can lead to missed or delayed prostate cancer diagnoses if not properly accounted for [38:00]; The optimistic future of prostate cancer: modern screening advances and the potential to reduce mortality [43:15]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/40876835

#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field 04/13/2026

#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field In this “Ask Me Anything” (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he’s covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated “peptides” common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, “research use only” labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your or our website at the . If you are not a subscriber, you can learn more about the subscriber benefits . We discuss: Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15]; What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30]; A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00]; Peptide case study—SS-31: mechanism of action, approved use in Barth syndrome, and other claimed effects [18:15]; Does the mechanistic rationale for SS-31 translate into measurable benefits? [22:15]; SS-31 continued: safety considerations, gray market risks, the balance of risk versus reward, and why it belongs in bucket #3 [26:00]; Peptide case study—melanotan-II: claimed effects, mechanism of action, safety, and side effects [30:45]; Melanotan-II continued: weighing the potential risks versus benefits and why it belongs in bucket #2 [36:30]; Peptide case study—CJC-1295: growth hormone–stimulating mechanism, claimed effects, and limited human data [40:15]; CJC-1295 continued: dosing uncertainty, risk-reward analysis, lack of long-term safety data, limited approved options, and why it belongs in bucket #2 [49:30]; Peptide case study—BPC 157: uncertain origins, broad claims, and weak mechanistic evidence [57:45]; BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15]; Other popular “gray market” peptides and why they mostly fail when under scrutiny [1:11:15]; How the evidence on peptides compares to rapamycin, and why the lack of data is the biggest concern [1:20:00]; Understanding peptide regulation: FDA approval, supplement oversight, and the risks of gray-market compounds [1:23:00]; Inside the gray market: how peptides are sold, regulated, and why testing cannot guarantee safety [1:26:45]; Limitations of oral peptides, and examples of peptides in bucket #4 [1:31:45]; The future of peptides: real therapeutic potential versus hype in the wellness market [1:35:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/40780450

#386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance 04/06/2026

#386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field’s central question: whether improving an aging clock score truly translates into meaningful clinical outcomes. We discuss: Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00]; How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00]; The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45]; The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45]; Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15]; The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00]; The DO-HEALTH study results: findings, takeaways, and open questions [27:45]; The DunedinPACNI study: how the model was developed and what it may add to the field [35:00]; The promise and limitations of aging clocks in measuring meaningful biological aging and predicting health outcomes [48:00]; Why aging clocks are not yet reliable as consumer tools and why traditional health metrics still matter most [52:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/40638900

#385 - AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more In this “Ask Me Anything” (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your or our website at the . If you are not a subscriber, you can learn more about the subscriber benefits . We discuss: Overview of episode topics, emphasizing the goal of providing actionable, real-world health guidance [1:30]; How health priorities and training strategies should evolve from early adulthood through older age [2:45]; Comparing the four major chronic diseases: which are most preventable, most uncertain, and most concerning [8:00]; Emerging strategies for dementia prevention: biomarkers, early detection, and new pharmacologic approaches [15:00]; How to use wearable data effectively: when it’s helpful, when it’s not, and how to avoid over-reliance [19:00]; DEXA scans: timing, interpretation, and limitations in body composition and bone density tracking [23:00]; Best practices for building sustainable health habits [30:15]; How to train your balance and stability [33:30]; How to recover from injuries and use setbacks to build strength and resilience [36:15]; High protein intake and the impact on mTOR: evaluating mechanisms versus real-world evidence on longevity [38:30]; Diet soda and artificial sweeteners: evaluating risks, benefits, and the importance of context [47:00]; How to balance enjoying life today with making choices that support long-term health and longevity [51:45]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/40550365

#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention 03/16/2026

#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention In this special episode, Peter takes a deep dive into obicetrapib, an investigational drug that has captured his attention and renewed interest in an entire class of therapies known as CETP inhibitors. He explains what obicetrapib is and how it works, revisits the history of CETP inhibitors and why earlier versions of these drugs failed—sometimes dramatically—and breaks down the key clinical trials designed to evaluate their impact on cardiovascular risk. Peter examines how obicetrapib influences major lipid biomarkers, including LDL cholesterol and lipoprotein(a) [Lp(a)], and discusses emerging evidence from a study that explored the drug’s effects on Alzheimer’s-related blood biomarkers. He also highlights intriguing findings in individuals carrying the APOE4 allele and reflects on what these early results may mean for both cardiovascular disease prevention and potential implications for Alzheimer’s risk, as well as how he is thinking about this therapy in the context of caring for his own patients. We discuss: Introducing obicetrapib: CETP inhibitor history, lipid biology, and early Alzheimer’s biomarker signals in APOE4 carriers [2:15]; CETP biology explained: lipoproteins, reverse cholesterol transport, and how CETP inhibition alters HDL and LDL particles [5:15]; The early CETP inhibitor story: why raising HDL cholesterol alone failed to deliver cardiovascular protection [13:45]; The rise and fall of early CETP inhibitors: torcetrapib, dalcetrapib, evacetrapib, and anacetrapib [18:30]; Why obicetrapib may succeed where earlier CETP inhibitors failed [23:30]; The BROADWAY trial: obicetrapib’s effects on LDL, ApoB, Lp(a), and residual cardiovascular risk [26:00]; Brain lipid metabolism and APOE4: how CETP inhibition may influence cholesterol transport in Alzheimer’s disease [30:45]; Findings from the substudy of the BROADWAY trial which looked at changes in biomarkers of Alzheimer’s disease [40:00]; Interpreting the BROADWAY Alzheimer’s biomarker results: limitations, cautious optimism, and the need for a dedicated prevention trial [46:45]; Why Peter is optimistic about obicetrapib: cardiovascular benefits, Lp(a) reduction, and the path toward approval [50:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/40420140

#380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats? | Layne Norton, Ph.D. 01/19/2026

#380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats? | Layne Norton, Ph.D. Layne Norton is a nutrition scientist and accomplished power athlete,who returns to The Drive for a conversation that departs from the show’s usual format. In this episode, Layne presents the evidence-based case that seed oils are not uniquely harmful under isocaloric conditions, while Peter steelmans the strongest versions of the opposing argument that seed oils are inherently harmful. They examine how scientific bias and evidence are evaluated, revisit the historical randomized controlled trials that shaped the seed oil controversy, and explore the mechanistic biology underlying LDL oxidation and atherosclerosis. Along the way, Layne unpacks the chemistry and processing of modern seed oils, assesses evolutionary and ancestral nutrition arguments, clarifies the relationship between seed oils, ultra-processed foods, and contemporary dietary patterns, and situates these questions within the larger context of lifestyle factors that drive cardiometabolic health. Layne concludes by offering practical considerations around dietary fats, cooking oils, and real-world food choices. We discuss: The idea behind this episode, biases, and evidence-based thinking [5:15]; The four core arguments behind claims that seed oils are harmful [12:30]; The Minnesota Coronary Experiment (MCE) [14:30]; The differences among saturated, monounsaturated, polyunsaturated, and trans fats, and why those differences matter for cardiovascular disease [18:30]; Missing trans fat data as a confounder in the Minnesota Coronary Experiment, other limitations of that study, and the challenge detecting meaningful differences in hard outcomes through nutrition research [24:00]; The Sydney Diet Heart Study (SDHS): an attempt to address the “duration problem” by enrolling a much higher-risk population [28:30]; Debating whether evidence from randomized trials supports the idea that seed oils are uniquely harmful once major confounders are removed [34:00]; The Rose Corn Oil trial: an often-cited study used to argue against polyunsaturated fats [36:30]; Three studies where replacing saturated fat with polyunsaturated fat produced different results than earlier trials [41:30]; Layne’s explanation for why the evidence is pointing towards cardiovascular risk reduction when substituting polyunsaturated fat for saturated fat [47:30]; What Mendelian randomization says about the causal role of LDL cholesterol in ASCVD [56:45]; The compounding effects of life-long exposure to high LDL cholesterol [1:06:45]; Does the linoleic acid (omega-6) content of seed oils cause inflammation? [1:13:45]; Does the linoleic acid (omega-6) content of seed oils increase oxidized LDL? [1:19:30]; Layne’s analogy to explain why lower LDL particle number outweighs higher per-particle oxidation risk when comparing polyunsaturated fats to saturated fats [1:26:15]; The role of oxidized LDL in CVD: exploring differences in a diet high in polyunsaturated fat (seed oils) versus high in saturated fat [1:28:00]; Examining whether industrial processing and solvent extraction of seed oils—especially residual hexane—could plausibly cause long-term harm [1:34:00]; The evolutionary and “ancestral diet” argument against seed oils [1:40:45]; Weighing concerns about industrial processing of seed oils against the totality of metabolic and cardiovascular evidence [1:47:30]; Practical considerations around dietary fats, cooking oils, and real-world food choices [1:50:00]; Comparing the health impact of seed oils with that of caloric intake and activity levels, and how to prioritize interventions [2:00:15]; More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/39763215

#379 - AMA #79: A guide to cardiorespiratory training at any fitness level to improve healthspan, lifespan, and long-term independence 01/12/2026

#379 - AMA #79: A guide to cardiorespiratory training at any fitness level to improve healthspan, lifespan, and long-term independence In this “Ask Me Anything” (AMA) episode, Peter brings together his most up-to-date thinking on cardiorespiratory fitness into a single, practical guide designed to help listeners structure training for maximal impact on healthspan, lifespan, and long-term independence. He explains why cardiorespiratory fitness is one of the strongest modifiable predictors of longevity, clarifies what zone 2 training actually represents and how it differs from higher-intensity work, and addresses persistent confusion around exercise volume, intensity, and time constraints. The discussion covers how to measure and track progress in zone 2, VO₂ max targets and age-adjusted goals, planning for the marginal decade, and how to balance zone 2 with higher-intensity training across different weekly volumes. Peter also outlines how cardio training should be tailored for beginners, experienced trainees, and older adults, with special considerations for women and guidance on avoiding the most common cardio-training mistakes. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your or our website at the . If you are not a subscriber, you can learn more about the subscriber benefits . We discuss: Rational for discussing cardiorespiratory fitness, zone 2, and VO₂ max despite having covered the topic extensively [2:30]; Why cardiorespiratory fitness and VO₂ max are powerful and modifiable predictors of all-cause mortality compared with other health metrics [7:30]; How age-related declines in VO₂ max constrain healthspan and everyday physical function [12:30]; The cardiorespiratory fitness triangle: how different training intensities contribute to building the aerobic base, the aerobic peak, and overall aerobic capacity [14:15]; The cellular mechanics of cardiorespiratory fitness: mitochondria, lactate, muscle fiber recruitment, and intensity thresholds [18:45]; The debate over whether zone 2 training has unique benefits or whether higher-intensity exercise alone is sufficient [27:15]; Balancing intensity and sustainability as training volume increases, and the important role of zone 2 training [32:15]; How to identify your zone 2 training intensity [34:45]; How to measure and track improvements in zone 2 fitness [40:00]; How to accurately measure VO₂ max: lab testing, field tests, and the limits of wearables [45:15]; How to set meaningful VO₂ max targets based on age, sex, long-term decline, and desired physical capabilities later in life [51:15]; How to structure and execute a zone 2 workout [59:45]; How strictly should zone 2 be maintained during a workout? [1:04:00]; How to design a VO₂ max training session: interval length, intensity, recovery, and progression strategies [1:07:00]; Why heart rate is not a reliable metric for titrating VO₂ max interval intensity [1:12:00]; Practical ways to monitor VO₂ max improvements [1:13:30]; How to balance zone 2 and VO₂ max training [1:15:30]; How to structure training for someone limited to 150 minutes per week of total exercise [1:19:00]; How to allocate 150 minutes per week of dedicated cardiorespiratory training between zone 2 and VO₂ max work [1:23:00]; How to structure training for someone with substantial available time who wants to maximize cardiorespiratory fitness [1:24:30]; Why spreading aerobic training across the week beats compressing volume into one session [1:26:15]; How beginners and metabolically unhealthy individuals should start cardiorespiratory training safely [1:28:00]; How “training age” determines the intensity and workload needed to continue improving cardiorespiratory fitness [1:31:15]; Why zone 2 training still matters for women (including postmenopausal women) [1:32:45]; How cardiorespiratory training should adapt with aging [1:35:45]; The most common mistakes people make when training cardiorespiratory fitness and how to avoid them [1:37:45]; How to break through a VO₂ max plateau [1:40:45]; The main takeaways about cardiorespiratory fitness and longevity [1:41:30]; Peter’s carve out: oral hygiene and Peter’s two-toothbrush system [1:43:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/39652050

#378 ‒ Women’s health and performance: how training, nutrition, and hormones interact across life stages | Abbie Smith-Ryan, Ph.D. 01/05/2026

#378 ‒ Women’s health and performance: how training, nutrition, and hormones interact across life stages | Abbie Smith-Ryan, Ph.D. Abbie Smith-Ryan is a leading researcher in exercise physiology whose work focuses on how training and nutrition influence body composition, metabolism, cardiovascular health, and women’s health across the lifespan, with particular attention on perimenopause and post-menopause. In this episode, Abbie explains how early exercise and play help build the foundation for bone health, muscle development, and cardiorespiratory fitness in girls, as well as how puberty and menstruation shape athletic performance, motivation, and recovery. She also explores how women can tailor training and nutrition across the menstrual cycle through smart fueling, hydration, and inflammation management; examines the evidence behind supplements such as creatine, omega-3s, and magnesium; and unpacks the metabolic and body composition changes that accompany the transition into perimenopause and menopause. Finally, she covers practical exercise programming for busy women, training and nutrition considerations during pregnancy and postpartum, and the evolving role of hormone therapy alongside lifestyle-based, evidence-driven approaches that help women better advocate for their health. We discuss: Abbie’s background in distance running and her interest in studying women’s health around exercise [3:00]; The role of early-life exercise in building lifelong bone, muscle, and cardiovascular health in girls [4:00]; Training principles for premenstrual girls, the risks of early specialization and delayed puberty from intense training, and how youth sport participation can shape bone and spinal health [7:15]; Nutrition as fuel in young female athletes: supporting training, growth, and performance [11:00]; Training and recovery across the menstrual cycle: recovery, nutrition, supplements, and practical strategies for performance support [16:00]; The benefits of creatine supplementation and importance of protein intake across the menstrual cycle [27:15]; How women should approach training intensity and volume across the menstrual cycle [33:00]; How to identify and monitor the perimenopausal transition and why this phase represents a critical window for exercise and nutrition interventions [37:15]; Case study: time-efficient exercise program for a busy, perimenopausal woman [42:00]; Why improving body composition is a better goal than weight loss, and how to set realistic fat-loss targets in midlife women [53:30]; How to preserve muscle and bone while using GLP-1 medications: resistance training, protein intake, and more [58:15]; Designing a three-hour-per-week training plan for sustainable body recomposition [1:03:30]; Abbie’s insights from her 20+ years of self-tracking: nutrient timing, injury prevention, excessive training, bone health, and more [1:07:15]; How pregnancy and the postpartum period affect body composition, and how consistent exercise and intentional nutrition can prevent a permanent shift in body fat or muscle mass [1:13:30]; Changes in muscle quality and metabolic flexibility during perimenopause and menopause, and how exercise may counteract hormonally driven sarcopenia [1:21:45]; The biggest open questions about women’s health: combining menopause hormone therapy with exercise, GLP-1 drugs, minimizing injury risk, and more [1:32:00]; How the training response differs between men and women, and the importance of type IIa muscle fibers [1:39:15]; Training advice for the hypothetical 70-year-old woman who has never exercised deliberately [1:47:00]; Misinformation about exercise and nutrition for women, injury risk, supplement hype, and the need for more nuanced messaging around hormones, recovery, and midlife training [1:53:30]; Benefits of hormone therapy in midlife women and its interaction with exercise and lifestyle interventions [2:00:15]; Peter’s overall take on how women should approach exercise volume and intensity at various life phases and time constraints [2:03:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/39519390

Building & Changing Habits | James Clear (#183 rebroadcast) 12/29/2025

Building & Changing Habits | James Clear (#183 rebroadcast) James Clear is the author of the New York Times bestseller Atomic Habits. His extensive research into human behavior has helped him identify key components of habit formation and develop the “Four Laws of Behavioral Change.” In this episode, James provides insights into how both good and bad habits are formed, including the influence of genetics, environment, social circles, and more. He points to changes one can make to cultivate more perseverance and discipline and describes the profound impact habits can have when tying them into one’s self-identity. Finally, James breaks down his “Four Laws of Behavioral Change” and how to use them to create new habits, undo bad habits, and make meaningful changes in one’s life. We discuss: Why James became deeply interested in habits [1:45]; Viewing habits through an evolutionary lens [6:00]; The power of immediate feedback for behavior change, and why we tend to repeat bad habits [9:15]; The role of genetics and innate predispositions in determining one’s work ethic and success in a given discipline [14:30]; How finding one’s passion can cultivate perseverance and discipline [23:15]; Advantages of creating systems and not just setting goals [29:15]; The power of habits combined with self-identity to induce change [36:30]; How a big environmental change or life event can bring on radical behavioral change [50:30]; The influence of one’s social environment on their habits [54:15]; How and why habits are formed [1:00:30]; How to make or break a habit with the “Four Laws of Behavior Change” [1:09:30]; Practical tips for successful behavioral change—the best strategies when starting out [1:16:15]; Self-forgiveness and getting back on track immediately after slipping up [1:30:30]; Law #1: Make it obvious—Strategies for identifying and creating cues to make and break habits [1:39:45]; Law #2: Make it attractive—examples of ways to make a new behavior more attractive [1:47:45]; Law #3: Make it easy—the 2-minute rule [1:58:45]; Law #4: Make it satisfying—rewards and reinforcement [2:03:30]; Advice for helping others to make behavioral changes [2:06:00]; More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/39461805

#377 ‒ Special episode: Understanding true happiness and the tools to cultivate a meaningful life—insights from past interviews with Arthur Brooks 12/22/2025

#377 ‒ Special episode: Understanding true happiness and the tools to cultivate a meaningful life—insights from past interviews with Arthur Brooks In this special episode of The Drive, Peter presents a curated “best of” conversation with bestselling author and previous guest Arthur Brooks, organized around four core themes: happiness itself, the forces that undermine it, the tools and practices that help cultivate it, and the courage required to live and love well. The episode brings together the most meaningful moments from two past interviews into a single, focused discussion that distills Brooks’ most insightful ideas and offers practical takeaways for building a life that's both successful and deeply happy. We discuss: Happiness vs. happy feelings, and how happiness and unhappiness can coexist [2:15]; The six fundamental emotions [5:30]; The three main “macronutrients” of happiness [15:00]; Enjoyment: one of the three macronutrients of happiness [22:45]; Satisfaction: one of the three macronutrients of happiness [30:45]; Sense of purpose: one of the three macronutrients of happiness [38:45]; Fame: one of the traps that hijack our happiness [46:30]; Success addiction, workaholism, and their detriment to happiness [49:15]; The reverse bucket list: one of Arthur’s tools and practices he recommends for moving past the traps that hijack our happiness [59:15]; Metacognition: one of Arthur’s tools and practices he recommends for moving past the traps that hijack our happiness [1:01:00]; Taking charge of your happiness: discipline, transcendent experiences, and other deliberate actions for “happier-ness” [1:11:30]; Tracking happiness: the biomarkers and micronutrients behind the macronutrients of happiness [1:22:45]; The value of minimizing the self and looking outward [1:30:45]; How Arthur surprised himself with his ability to improve his happiness [1:34:45]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/39444860

#376 - AMA #78: Longevity interventions, exercise, diagnostic screening, and managing high apoB, hypertension, metabolic health, and more 12/15/2025

#376 - AMA #78: Longevity interventions, exercise, diagnostic screening, and managing high apoB, hypertension, metabolic health, and more In this “Ask Me Anything” (AMA) episode, Peter tackles a wide-ranging set of listener questions spanning lifespan interventions, exercise, cardiovascular risk reduction, time-restricted eating, blood pressure management, hormone therapy, diagnostics, and more. Peter reveals the single most important lever for extending healthspan and lifespan, and explains how he motivates midlife patients using the Centenarian Decathlon framework. He discusses the importance of addressing high apoB and cholesterol even in metabolically healthy individuals with calcium scores of zero, how to manage high blood pressure, and how to accurately evaluate metabolic health beyond HbA1c. Additional topics include time-restricted eating, practical considerations around ultra-processed foods, nuanced approaches to HRT for women and TRT for men, and why early and expanded screening for chronic disease—colonoscopy, PSA, coronary imaging, low-dose CT—can be lifesaving. He also offers insights into treating prediabetes, crafting exercise programs for those short on time, and safely incorporating high-intensity training in older adults. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your or our website at the . If you are not a subscriber, you can learn more about the subscriber benefits . We discuss: Introducing a wide-ranging AMA: practical perspectives on lifespan interventions, metabolic health, diet, hormones, diagnostics, and more [2:45]; Why exercise is the most powerful single intervention for lifespan and healthspan [4:15]; How Peter motivates midlife patients to prioritize exercise [6:00]; Why lifespan and healthspan should not be treated as competing priorities and how choosing sustainable interventions benefits both [9:30]; Why high apoB deserves treatment even in a metabolically healthy patient with a CAC score of zero [14:00]; Managing hypertension: ideal targets for blood pressure, lifestyle levers, and why early pharmacology matters [18:15]; Assessing metabolic health beyond HbA1c: fasting insulin, triglycerides, lactate, zone 2, and more [23:30]; How to avoid common self-sabotaging patterns by choosing sustainable habits over extreme health interventions [26:00]; Time-restricted eating: minimal effect beyond calorie control, implications for protein intake, and practical considerations for implementing it [28:00]; Ultra-processed foods: definitions, real-world risks, and practical guidelines for smarter consumption [30:30]; How women should prepare for menopause and think about hormone replacement therapy: early planning, symptom awareness, and guidance on HRT [36:45]; Testosterone replacement for aging men: indications, benefits, and safe clinical management [39:45]; Why Peter recommends earlier and more aggressive screening tests than guidelines suggest: colonoscopies, coronary imaging, PSA, Lp(a), and low-dose CT scans, and more [43:30]; Full-body MRI screening: benefits, limitations, potential false positives, and the importance of physician oversight [47:15]; Prediabetes: individualized treatment strategies using tailored combinations of nutrition, sleep, and training interventions [51:00]; Time-efficient training plans for people with only 30 minutes per day to exercise [53:00]; How to safely introduce high-intensity exercise for older adults [55:00]; Timed dead hangs and ripping phone books: a playful look at Peter’s early attempts to impress his wife [57:15]; Peter’s carve out: The Four Kings documentary about a golden era of boxing [1:01:15]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/39351720

#375 - Ketogenic diet, ketosis & hyperbaric oxygen: metabolic therapies for weight loss, cognition, Alzheimer’s & more | Dom D’Agostino, Ph.D. 12/08/2025

#375 - Ketogenic diet, ketosis & hyperbaric oxygen: metabolic therapies for weight loss, cognition, Alzheimer’s & more | Dom D’Agostino, Ph.D. Dom D'Agostino is a neuroscientist and professor at the forefront of metabolic therapies, including ketogenic diets, exogenous ketones, and hyperbaric oxygen. In this episode, Dom breaks down nutritional versus supplemental ketosis, defines meaningful ketone thresholds, and outlines practical ways to achieve ketosis. He explains how a ketogenic diet can support metabolic health and weight loss, and advises on how to maintain adequate protein and avoid common mistakes. Dom surveys the growing landscape of exogenous ketones—from salts and esters to 1,3-butanediol—and effective pairings like caffeine, MCT oil, and alpha-GPC. He highlights the role of ketogenic therapy in cancer (particularly glioblastoma) and its promise for neurodegenerative diseases. The conversation also covers recommended hyperbaric oxygen protocols for brain injuries and cognitive function, situations where fasting or ketones offer cognitive and anti-inflammatory benefits, and touches on the carnivore diet as a ketogenic variant with potential relevance for autoimmune and metabolic conditions. We discuss: Dom and Peter’s shared interest in ketosis, and Dom’s scientific journey [2:30]; Dom’s work for the Navy on oxygen toxicity [7:00]; Nutritional ketosis defined: physiology, biomarkers, and how fasting and diet generate therapeutic ketones [15:00]; The historical roots of ketogenic diets in epilepsy treatment, and evidence showing ketones reduce seizure activity and strengthen brain resilience [19:00]; Dom’s personal experience on the ketogenic diet: tracking macros, getting enough protein, and monitoring ketone levels [24:15]; Using a ketogenic diet for weight loss: Dom’s guidance on protein, fiber, calorie tracking, lipid monitoring, and more [31:00]; Protein on ketogenic diets: Dom’s rationale for higher intake and muscle preservation [38:00]; Incorporating carbohydrates into keto: timing, high-fiber foods, and other considerations [41:30]; The carnivore diet: whether this diet induces ketosis, how it functions metabolically, and why it may help individuals with autoimmune conditions [44:15]; Early exogenous ketones: how 1,3-butanediol works, its liver toxicity risk, and why ketone esters replaced it [48:15]; The progression of exogenous ketones: why BHB monoesters and ketone salts emerged as better alternatives to 1,3-butanediol for ketone supplementation [59:30]; Ketone salts: easing the transition into ketosis, dosing, and how they compare to ketone esters [1:04:00]; The differences between D- and L-β-hydroxybutyrate, and how racemic mixtures may elevate ketones longer and offer unique biological effects [1:09:30]; How ketosis may boost NAD, and why NAD supplements have fallen short so far [1:16:30]; Emerging evidence for using a ketogenic diet to treat anorexia and other psychiatric disorders [1:20:30]; Potential cognitive and performance benefits of ketone supplementation, and why pushing ketones too high can be dangerous [1:23:45]; Applications for ketone esters, and why ketone salts or MCT-blended formulations may be safer and more practical for most people [1:29:15]; The role of a ketogenic diet in treating cancer [1:34:45]; The potential of a ketogenic diet for treating Alzheimer’s disease [1:45:45]; Tools for cognitive enhancement: ketones, alpha-GPC, MCT, caffeine, strategic fasting, and more [1:53:45]; Hyperbaric oxygen therapy for concussion, TBI, PTSD, and cognitive function, including protocols and dosing approaches [1:55:30]; Peter’s takeaways, recommended products, and additional resources to learn more [2:03:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/39259135

#374 - The evolutionary biology of testosterone: how it shapes male development and sex-based behavioral differences, | Carole Hooven, Ph.D. 12/01/2025

#374 - The evolutionary biology of testosterone: how it shapes male development and sex-based behavioral differences, | Carole Hooven, Ph.D. Carole Hooven is a human evolutionary biologist whose research centers on testosterone, sex differences, and behavior. In this episode, she explores how prenatal testosterone orchestrates male development in the body and brain, how early hormonal surges shape lifelong behavioral tendencies, and what rare natural experiments—such as 5-alpha-reductase deficiency—reveal about the biology of sex differentiation. She discusses distinct male and female aggression styles through an evolutionary lens, how modern environments interact with ancient competitive drives, and the implications of attempting to suppress them. The conversation also covers testosterone across the lifespan, the role of hormone therapy in both men and women, and Carole’s own experience after surgical menopause, culminating in a broader discussion of masculinity, cultural narratives, and the consequences of denying biological sex differences. We discuss: How Carole became interested in exploring the biological and evolutionary roots of sex differences and the role of testosterone [2:30]; How testosterone and other hormones influence sex differences in aggression and behavior across species [9:45]; How chromosomes, the SRY gene, and early hormones direct embryonic sexual differentiation [12:15]; A stark contrast of male social bonding compared to females, and evolutionary parallels in chimpanzees [19:30]; How hormones like DHT shape sexual differentiation, and how 5⍺-reductase deficiency reveals the distinct roles of these hormones [22:45]; How sex chromosomes and prenatal testosterone shape early brain development and explain sex differences in childhood behavior [31:30]; How gamete differences shape reproductive strategies, energetic costs, and sex-specific behavior [42:30]; How evolutionary biology shapes sex differences in play, aggression, and conflict resolution (and how modern environments and cultural messaging can disrupt those patterns) [49:00]; Why males commit disproportionately more violent crime, and how cultural and environmental forces shape aggression [1:01:00]; Why females evolved different behavioral strategies: nurturing, risk aversion, and the cultural norms that override biology [1:04:00]; Whether male aggression is still necessary in modern society, why the underlying biological drives persist, and how modern society redirects these drives [1:06:30]; How testosterone levels naturally shift to support fatherhood and caregiving [1:13:30]; How testosterone shapes male mating strategies, and why long-term pair-bonding persists even when reproduction is no longer at stake [1:18:30]; The distinct roles of estrogen in male development, mood, libido, and muscle [1:25:00]; How evolution, health, lifestyle, and androgen receptor biology shape modern testosterone replacement therapy (TRT) [1:34:15]; Carole’s experience with hormone replacement therapy (HRT), and the risks associated with TRT in younger men [1:45:15]; How Carole rebuilt after controversy: leaving academia and recommitting to scientific honesty [1:51:30,]; Carole’s next book: examining masculinity, cultural narratives, and the cost of denying biological sex differences [1:57:30]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/39175985

The impact of gratitude, serving others, embracing mortality, and living intentionally | Walter Green (#288 rebroadcast) 11/24/2025

The impact of gratitude, serving others, embracing mortality, and living intentionally | Walter Green (#288 rebroadcast) Walter Green is a remarkable philanthropist, mentor, author of This Is the Moment!, and founder of the impactful “Say It Now” movement. In this episode, Walter delves into the unique insights gained from his challenging upbringing, discusses embracing mortality, and highlights the mindset of “finishing strong.” He shares insights on intentionality, thinking in reverse, saying “no,” prioritizing relationships, and the essence of focusing on others. The conversation focuses on the “Say It Now” movement, which stresses the importance of expressing sentiments to loved ones well before the end of life. We discuss: How Peter and Walter met through Ric Elias [3:30]; The unique perspectives and life lessons provided by Walter’s challenging childhood [6:00]; Walter’s harrowing experience with a sudden mental breakdown and his subsequent recovery with the help of therapy [12:15]; A diverse professional journey ending in great success [19:15]; The birth of a movement: celebrating friendships through public tributes and expressing gratitude to those who have shaped your life’s journey [23:30]; Intentionality, thinking in reverse, saying “no”, and other guiding principles for Walter [30:45]; Walter’s global journey of gratitude on his 70th birthday, visiting friends, and creating memorable experiences [40:15]; The profound impact of acknowledging and expressing gratitude for the people who contribute to our lives [47:15]; The key elements for creating meaningful connections and cultivating deep, authentic friendships [53:15]; The “Say It Now” movement: the inspiration behind the remarkably impactful initiative [59:15]; What “finishing strong” means to Walter [1:08:15]; Finding peace at the end of life through expressing gratitude and finding purpose in serving others [1:16:45]; Resources to learn about “Say It Now” [1:27:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/39089510

#373 – Thyroid function and hypothyroidism: why current diagnosis and treatment fall short for many, and how new approaches are transforming care | Antonio Bianco, M.D., Ph.D. 11/17/2025

#373 – Thyroid function and hypothyroidism: why current diagnosis and treatment fall short for many, and how new approaches are transforming care | Antonio Bianco, M.D., Ph.D. Antonio Bianco is a world-renowned physician-scientist and expert in thyroid physiology and metabolism. In this episode, Antonio explores the complex biology of thyroid hormone production, conversion, and regulation—highlighting how deiodinase enzymes modulate hormone activity at the tissue level and why that matters for interpreting lab results. He discusses the shortcomings of relying solely on TSH as a marker of thyroid function, the ongoing debate around combination therapy with T3 and T4 versus standard T4 treatment, and how genetics, tissue sensitivity, and individual variability influence thyroid hormone metabolism. The conversation also examines how hypothyroidism affects energy, mood, cognition, and longevity; why some patients remain symptomatic despite “normal” labs; and how future research could reshape treatment paradigms. We discuss: How the thyroid produces, stores, and activates hormones like T4 and T3 to finely regulate thyroid activity [2:45]; How fasting alters thyroid hormones to conserve energy [12:45]; Action of the deiodinases: how D1, D2, and D3 enzymes control the activation and inactivation of thyroid hormones [19:15]; The normal function of thyroid hormone and the roles of the hypothalamus, pituitary gland, and deiodinases in maintaining hormonal balance [23:30]; Why understanding thyroid physiology is essential for proper diagnosis and treatment of hypothyroidism [33:45]; Testing for thyroid hormones: understanding free vs. total levels, the limitations of current T3 assays, best practices, and more [36:00]; Genetic and sex-based variability in thyroid hormone regulation and their limited clinical significance [43:45]; Hyperthyroidism: causes, symptoms, diagnosis, and treatment options [46:00]; Hypothyroidism: diagnosis and autoimmune causes of hypothyroidism [56:30]; More on hypothyroidism: diagnostic biomarkers, antibody patterns, and non-autoimmune presentations [1:05:00]; Thyroid hormone replacement therapy [1:15:15]; More on thyroid replacement strategies: exploring the evidence gaps, mortality signals, effects on lipids, and more [1:28:00]; Hypothyroidism basics: causes, antibody implications (including pregnancy), and how to make the diagnosis before choosing therapy [1:35:15]; Thyroid medication: compounded controlled-release T3, brand name versus generic, and what Antonio prescribes to newly diagnosed hypothyroid patients [1:42:45]; Redefining treatment success: why normalizing TSH isn’t always enough for patients with hypothyroidism [1:54:45]; Case studies: analysis of two unusual cases of thyroid disease [1:57:00]; Dangers of supplementing with high levels of iodine, and female-specific risk of thyroid disease [2:05:45]; Case study of a patient who presents with elevated TSH but no symptoms [2:09:30]; How future research could reshape treatment, and Antonio’s new book called “Rethinking Hypothyroidism” [2:13:15]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/39029430

#372 - AMA #77: Dietary fiber and health outcomes: real benefits, overhyped claims, and practical applications 11/10/2025

#372 - AMA #77: Dietary fiber and health outcomes: real benefits, overhyped claims, and practical applications In this “Ask Me Anything” (AMA) episode, Peter breaks down the science of dietary fiber, moving beyond the blanket advice to “eat more fiber” to uncover what it actually does in the body and where its benefits are truly supported by evidence. He explains how different types of fiber—soluble, insoluble, viscous, and fermentable—affect digestion, satiety, weight management, and glycemic control, and compares their impact to other, more potent metabolic tools. Peter also examines how certain fibers influence lipid metabolism and cardiovascular risk, evaluates the strength of evidence for fiber’s role in colorectal cancer prevention, and highlights why some individuals may not tolerate specific fibers well. The discussion concludes with practical guidance on moving past generic fiber targets toward a more strategic and personalized approach that maximizes the true benefits of fiber. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your or our website at the . If you are not a subscriber, you can learn more about the subscriber benefits . We discuss: Why it’s time to re-examine the evidence behind dietary fiber recommendations [2:00]; Why it’s hard to isolate fiber’s true effects on health: the limits of nutritional epidemiology [5:45]; Defining dietary fiber: what it is, how it’s digested, and why different types have different effects [8:15]; Understanding fiber properties: how solubility, viscosity, and fermentability shape its effects in the body [11:15]; Resistant starches explained: types, food sources, and how cooking and cooling influence their benefits [16:30]; A framework for evaluating each of the major health claims linked to fiber [19:15]; How fiber can support weight loss: mechanisms, realistic expectations, and its complementary role to broader dietary strategies [20:30]; How fiber modestly improves glycemic control by reducing glucose spikes and insulin demand [26:15]; How fiber modestly lowers LDL cholesterol and supports cardiovascular health [34:30]; How fiber compares to other available tools and strategies for managing lipids, blood sugar, and weight [42:00]; Fiber’s role in colon cancer prevention: mechanisms, evidence, and limitations [45:30]; Is fiber necessary for colon cancer prevention in otherwise healthy individuals? [53:30]; Why some people have adverse reactions to certain types of fiber, and how to manage them [56:00]; A general strategy for dietary fiber: combine multiple fiber types through whole foods and supplements [58:45]; Why total fiber intake is more important than the ratio of soluble-to-insoluble fiber [1:02:45]; The optimal timing and context for consuming fiber to maximize blood sugar control and metabolic benefits [1:05:00]; How food processing affects the functional properties of fiber, the differences between supplement forms and natural sources, and why whole foods generally remain the best option [1:06:45]; Fiber’s potential to interfere with medication absorption [1:09:30]; How to safely increase fiber intake: ramp up gradually and stay hydrated [1:12:00]; Final takeaway on fiber: modest benefits, strong rationale, low downside [1:13:00]; Peter’s carve-out: lessons and inspiration from the Acquired podcast [1:14:30]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/38934010

#371 – Women’s sexual health: desire, arousal, and orgasms, navigating perimenopause, and enhancing satisfaction | Sally Greenwald, M.D., M.P.H. 11/03/2025

#371 – Women’s sexual health: desire, arousal, and orgasms, navigating perimenopause, and enhancing satisfaction | Sally Greenwald, M.D., M.P.H. Sally Greenwald is an OB-GYN who specializes in women’s sexual health from a hormonal and physiologic perspective, with expertise spanning desire, arousal, pelvic floor function, contraception, and menopause care. In this episode, she explains why sexual health is a vital component of overall well-being, exploring topics such as the drivers of desire, the anatomy of sexual function, myths and realities around orgasm, and the role of hormones in perimenopause and menopause. She also covers vaginal and pelvic health, pain with sex, evidence-based therapies for low desire and arousal, how contraception and medications can affect sexual function, and practical strategies for enhancing sexual satisfaction and maintaining intimacy across life stages. This episode offers a comprehensive, evidence-based discussion with immediate real-world relevance for women as well as for men who want to better understand their partners. We discuss: How sexual health influences physical health, emotional well-being, and relationships [3:15]; Understanding the physiology of the female orgasm, sexual comfort and satisfaction, and the disparity between men and women [12:45]; Foreplay, the science of desire, and methods to help women cultivate arousal and connection [19:00]; The physiology and sources of female lubrication, the role of clitoral nerve anatomy in pleasure, and the use of lubricants and vibrators to enhance comfort and sexual health [23:45]; Understanding female anatomy and what is needed for orgasm [31:15]; Understanding sexual desire, how to cultivate it, the role of hormones, and testosterone therapy in women [41:15]; Personalizing perimenopause care: how desire for ovulation guides the choice between contraception and menopausal hormone therapy [49:30]; Considerations for choosing contraceptives and hormonal therapies during perimenopause [59:45]; Factors negatively affecting desire, and why female libido persists with age and fluctuates across the menstrual cycle [1:11:00]; How sexual trauma and physical pain can affect sexual health, and evidence-based strategies for recovery [1:15:15]; Vaginal care routine: lubricants, moisturizers, topical hormones, and other approaches for vaginal health [1:19:15]; Tips for sexually satisfying your female partner [1:25:45]; The pharmacology of arousal: various treatments for low sexual desire in women [1:30:30]; Sex during and after pregnancy: impact on arousal, safety of sex, and how to manage postpartum recovery and pain [1:37:45]; How Sally would redesign sex education [1:42:15]; Sally’s optimism about a new era in women’s sexual health [1:49:00]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/38775435

Longevity 101: a foundational guide to Peter’s frameworks for longevity, and understanding CVD, cancer, neurodegenerative disease, nutrition, exercise, sleep, and more (re-broadcast) 10/27/2025

Longevity 101: a foundational guide to Peter’s frameworks for longevity, and understanding CVD, cancer, neurodegenerative disease, nutrition, exercise, sleep, and more (re-broadcast) In this special episode, Peter provides a comprehensive introduction to longevity, perfect for newcomers or those looking to refresh their knowledge. He lays out the foundational concepts of lifespan, healthspan, and the marginal decade. Additionally, Peter discusses the four main causes of death and their prevention, as well as detailing the five key strategies in his longevity toolkit to improve lifespan and healthspan. Detailed show notes provide links for deeper exploration of these topics, making it an ideal starting point for anyone interested in understanding and improving their longevity. We discuss: Key points about starting exercise as an older adult [2:45]; Overview of episode topics and structure [1:45]; How Peter defines longevity [3:45]; Why healthspan is a crucial component of longevity [11:15]; The evolution of medicine from medicine 1.0 to 2.0, and the emergence of medicine 3.0 [15:30]; Overview of atherosclerotic diseases: the 3 pathways of ASCVD, preventative measures, and the impact of metabolic health [26:00]; Cancer: genetic and environmental factors, treatment options, and the importance of early and aggressive screening [33:15]; Neurodegenerative diseases: causes, prevention, and the role of genetics and metabolic health [39:30]; The spectrum of metabolic diseases [43:15]; Why it’s never too late to start thinking about longevity [44:15]; The 5 components of the longevity toolkit [46:30]; Peter’s framework for exercise—The Centenarian Decathlon [47:45]; Peter’s nutritional framework: energy balance, protein intake, and more [58:45]; Sleep: the vital role of sleep in longevity, and how to improve sleep habits [1:08:30]; Drugs and supplements: Peter’s framework for thinking about drugs and supplements as tools for enhancing longevity [1:13:30]; Why emotional health is a key component of longevity [1:17:00]; Advice for newcomers on where to start on their longevity journey [1:19:30]; and More. Connect With Peter on , , and /episode/index/show/peterattiadrive/id/38779785

The Peter Attia Drive

TOPICS